NEWS
Our Latest News
ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions
Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics.
Acquisition by ARCHIMED’s NAMSA makes it the preeminent contract research organization for medtech lab testing
March
2,
2021
ARCHIMED strengthens its North American capabilities
January
26,
2021
ARCHIMED’s Direct Healthcare Group sees annual revenue more than double through four Buy-and-Build purchases over nine months
January
25,
2021
ARCHIMED’s BOMI Group enters new geographies and market segments through six Buy-and-Build acquisitions made over eight months
January
25,
2021
ARCHIMED buys Germany’s Zyto Group of Cancer Diagnostics companies in partnership with owners and management
January
12,
2021
ARCHIMED’s NAMSA announces key acquisition of Syntactx
January
5,
2021
368